I am working on a project proposal for an exam, it involves a budget of 1M euros and I got to design a genomic study. I chose a GWAS to assess altered gene expression after covid19 that leads to long-COVID. I thought about 3 cohorts:

Case cohort1: Long-Covid patients (N: 3,000)

Case cohort2: Fully recovered patients (N: 3000)

Control cohort: healthy patients. (N: 6000)

Would it make sense to run two GWAS for the two case cohorts against the control cohort (cohort1/controls and cohort2/controls) then do a miami plot to see if there are some hits that differs from the two cohorts, and pick the ones only presented in the Long-covid for further assessment?

The study will also be supported by a validation step for both gwas. What do you think about this idea? Would it make sense or the fully-recovered patients against control cohorts is totally useless? Thank you in advance


In the end I manage to do 2 cohorts 1: Long Covid Patients (1300N) 2: NON Long Covid Patients that had Covid (1300).

It was the most rational thing to do, and professor liked it. So that's how I manage in th end.


Your Answer

By clicking “Post Your Answer”, you agree to our terms of service, privacy policy and cookie policy

Not the answer you're looking for? Browse other questions tagged or ask your own question.